

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: SOLOMON=1R

In re Application of:)	Conf. No.:	3910
)		
Beka SOLOMON)	Art Unit:	1642
)		
Appln. No.:)	Examiner:	G. Bansal
09/441,140)		
)		
Filed:)	Washington,	D.C.
November 16, 1999)		
)		
For:)	August 22,	2002
PREVENTION OF PROTEIN)		
AGGREGATION)		

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir :

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:

(Check one of the boxes A-D)

A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.

B. before the mailing date of a first office action on the merits.

C. after (A) and (B) above, but before final rejection or allowance, and Applicants have made the necessary certification (box "i" below) or paid the necessary fee (box "ii" below).

(Check one of the boxes "i" and "ii" below:)

i. Counsel certifies that, upon information and belief, each item of information listed herein was either

(a) first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

(b) not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in §1.56(c) more than three months prior to the filing of this IDS.

ii. Credit Card Payment Form, PTO-2038, is attached authorizing payment of the fee set forth in §1.17(p), presently believed to be \$180.

D. after (A), (B) and (C) above, but before payment of the issue fee: Applicant(s) petitions under 37 CFR §1.97(d) for consideration of this IDS. ***(use one and delete other of following and this note)*** A check (check no. _____) for/ Credit Card Payment Form, PTO-2038, is attached authorizing payment of the fee set forth in §1.17(i), presently believed to be \$130 is enclosed. Counsel certifies that, upon information and belief, each item of information listed herein was either

(Check one of the boxes "a" and "b" below)

(a) first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

(b) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was not known to any individual designated in §1.56(c) more than three months prior to the filing of this IDS.

2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form PTO-1449) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except as explained below.

(check boxes A and/or B and fill in blanks, if appropriate)

A. Document(s) _____ is (are) deemed substantially cumulative to document(s) _____, and, in accordance with §1.98(c), only a copy of each of the latter documents is enclosed.

B. Certain documents were previously cited by or submitted to the Office in the following prior application(s), which are relied upon under 35 U.S.C. 120:

(insert serial numbers and filing dates of prior applications)

Applicant(s) identifies these documents by attaching hereto copies of the forms PTO-892 and PTO-1449 from the files of the prior application(s) or a fresh PTO-1449 listing these documents, and request that they be considered and made of record in accordance with §1.98(d). Per 37 CFR §1.98(d),

copies of these documents need not be filed in this application.

3. Document(s) _____ is (are) not in the English language. In accordance with §1.98(c), Applicant(s) states:

An English translation of each document _____ (or of the pertinent portions thereof), or a copy of each corresponding English-language patent or application, or English-language abstract (or claim) is enclosed.

A concise explanation of the relevance of document(s) _____ is found in the attached _____ search report (see reply to Comment 68 in the preamble to the final rules; 1135 OG 13 at 20).

A concise explanation of the relevance of document(s) _____ is set forth as follows:
(insert concise explanation of relevance)

A concise explanation of the relevance of document(s) _____ can be found on page(s) _ of the specification.

A concise explanation of document(s) _____ can be found on the attached sheet.

4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

5. Other information being provided for the examiner's consideration follows:
(insert other information)


6. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a

representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:



Roger L. Browdy
Reg. No. 25,618

624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001-5303
Telephone: (202) 628-5197
Facsimile: (202) 737-3528

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(use as many sheets as necessary)*

Sheet 1 of 2

Complete if Known

Application Number	09/441,140
Filing Date	November 16, 1999
First Named Inventor	Beka SOLOMON
Group Art Unit	1642
Examiner Name	G. Bansal
Attorney Docket Number	SOLOMON=1R

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AE	5,750,349	A	Suzuki et al	05-12-1998	
	AF	5,753,624	A	McMichael et al	05-19-1998	
	AG	5,851,996	A	Kline	12-22-1998	
	AH	5,955,317	A	Suzuki et al	09-21-1999	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ⁵ (if known)				
	AI	WO	95/31996	A1	MILKHAUS LABORATORY	11-30-1995		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AJ	DELIMASTRO et al, "Immunogenicity of filamentous phage displaying peptide mimotopes after oral administration", <u>Vaccine</u> 15(11):1276-1285 (1997)	
	AK	DODART et al, "Immunization reverses memory deficits without reducing brain A β burden in Alzheimer's disease model", <u>Nat Neurosci</u> 5(5):452-457 (2002) (published online April 8, 2002, pp. 1-6)	
	AL	JANUS et al, "A β peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease", <u>Nature</u> 408(6815):979-982 (2000)	
	AM	MANOUTCHARIAN et al, "Phage Displayed Biomolecules As Preventive and Therapeutic Agents", <u>Curr Pharm Biotechnol</u> 2(3):217-223 (2001)	
	AN	MORGAN et al, "A β peptide vaccination prevents memory loss in an animal model of Alzheimer's disease" <u>Nature</u> 408(6815):982-985 (2000)	
	AO	SEUBERT et al, "Isolation and quantification of soluble Alzheimer's β -peptide from biological fluids", <u>Nature</u> 359(6393):325-327 (1992)	
	AP	Elan Internet Press Release, "Elan and AHP provide an update on the phase 2A Clinical Trial of AN-1792", January 18, 2002 (www.elan.com/NewsRoom)	
	AQ	Elan Internet Press Release, "Elan and Wyeth provide update on status of Alzheimer's collaboration", March 1, 2002 (www.elan.com/NewsRoom)	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

RAMQ

APPLICANT(S): Beka SOLOMON
APPLICATION NO: 09/441,140

DOCKET NO.: SOLOMON=12
CONF. NO: 3910

THE PATENT AND TRADEMARK OFFICE STAMP
HEREON ACKNOWLEDGES RECEIPT OF THE
FOLLOWING PAPERS:

- FEES \$ 180⁰⁰
- PTO FORM 2038 (CH. # _____)
- EXTENSION OF TIME (_____ MONTHS)
- TRANSMITTAL LETTER
- MISSING PARTS RESPONSE WITH DECL
- AMENDMENT/RESPONSE (circle one)
 - PRELIMINARY SUPPLEMENTAL
- APPLICATION DATA SHEET
- RESTRICTION/ELECTION REPLY
- SEQUENCE LISTING WITH DISK
- RCE / CPA TRANSMITTAL (circle one)
- NOTICE OF APPEAL
- APPEAL BRIEF (TRIPPLICATE)
- REPLY BRIEF (TRIPPLICATE)
- OTHER _____

RECEIVED
TECH CENTER 1600/2900
02 AUG 22 PM 2:35

- ASSIGNMENT
- INFORMATION DISCLOSURE STATEMENT
- FORM 1449 & 13 PATENTS/PUBS
- PRIORITY DOCUMENT(S) NO. _____
- DECLARATION UNDER § _____
- LETTER TO DRAFTSMAN
- _____ SHEETS OF DRAWINGS
- ISSUE FEE TRANSMITTAL FORM
- MAINTENANCE FEE LETTER